复宏汉霖h药小细胞肺癌数据亮眼 国产创新药大放异彩
内容来源于：复宏汉霖
2022年5月30日，复宏汉霖（2696.hk）宣布，公司首个创新药产品h药 汉斯状®（斯鲁利单抗）的多项临床研究将在2022年美国临床肿瘤学会（asco）年会进行发布。一项h药针对一线广泛期小细胞肺癌（es-sclc）的国际多中心iii期临床研究（astrum-005）获选为口头报告，该研究由吉林省肿瘤医院程颖教授担任主要研究者。这也将是中国自主研发的抗pd-1单抗首次在肺癌领域以口头报告形式在asco年会进行汇报，充分展现出中国医药企业的创新生物药领先的研发能力和国际临床运营实力。详细研究数据将在6月5日进行公布，敬请期待。
同时，中国人民解放军东部战区总医院秦淮医疗区秦叔逵教授和上海东方医院李进教授共同牵头开展的h药针对微卫星高度不稳定（msi-h）实体瘤的关键性注册ii期临床研究（astrum-010）再次入选asco年会，数据更新将以海报形式展示。基于该试验结果，h药已正式获批用于治疗msi-h实体瘤。
asco年会是肿瘤治疗领域最重要、最具影响力的国际会议之一，旨在展示当前国际最前沿的临床肿瘤学科研成果和肿瘤治疗技术。本届年会将于美国中部时间6月3日-7日召开。此次将展示的相关临床研究包括：
• astrum-005
论文题目：创新型抗pd-1抗体斯鲁利单抗联合化疗与单纯化疗在一线治疗广泛期小细胞肺癌中的比较：一项国际、随机ⅲ期临床研究（摘要编号：8505）
主要研究者：程颖，吉林省肿瘤医院
展示形式：口头报告
专场：口头摘要专场/肺癌—非小细胞局部/小细胞/其他胸部肿瘤
报告时间：2022年6月5日，9:57 am - 10:09 am 美国中部夏令时
• astrum-010
论文题目：创新型抗pd-1抗体斯鲁利单抗在经治疗、不可切除或转移性微卫星高度不稳定或错配修复缺陷（msi-h/dmmr）实体瘤患者中开展的ⅱ期临床试验疗效及安全性结果更新（摘要编号：2592）
联合主要研究者：秦叔逵，中国人民解放军南京八一医院；李进，同济大学附属东方医院
展示形式：海报
时间：2022年6月3日，美国中部夏令时
• 实体瘤i期研究
论文题目：创新型人源化抗pd-1单克隆抗体斯鲁利单抗在晚期实体瘤患者中的一项ⅰ期临床试验（摘要编号：e14560）
展示形式：摘要
h药小细胞肺癌数据亮眼
国产创新药风采绽放
小细胞肺癌（sclc）占肺癌总数的15%-20%，是肺癌中侵袭性最强的亚型，分为局限期小细胞肺癌（ls-sclc）和广泛期小细胞肺癌，二者共同点是恶性程度高、转移早、疾病进展迅速，总体预后不良。免疫检查点抑制剂的出现为es-sclc领域的治疗带来新希望。
astrum-005为一项在既往未接受过治疗的es-sclc患者中比较h药注射液联合化疗（卡铂-依托泊苷）及安慰剂联合化疗（卡铂-依托泊苷）的临床有效性和安全性的随机、双盲、国际多中心、iii期临床研究。该试验在中国、土耳其、欧盟波兰、格鲁吉亚等多个国家共开设128个试验中心，其中114个试验中心有受试者参与了筛选，共入组585例受试者，其中约31.5%为高加索人。2021年12月，公司宣布astrum-005已于中期分析达到主要研究终点总生存期（os）。研究数据显示，h药联合化疗在总体人群和亚洲人群均可延长os，显示出良好的疗效和安全性。充分的国际临床试验数据也有望支持h药在欧盟、美国等主流法规市场的申报，为全球临床应用奠定基础。
目前，公司h药针对es-sclc的上市注册申请（nda）已获国家药监局受理，有望成为全球首个一线治疗sclc的抗pd-1单抗。h药联合化疗近期也被《2022 csco小细胞肺癌诊疗指南》推荐作为es-sclc一线疗法，是对h药临床疗效及安全性的高度认可。此外，h药用于sclc治疗也于近期获得美国fda授予的孤儿药资格认定（orphan-drug designation），公司亦计划于2022年在欧盟递交h药针对es-sclc适应症的上市注册申请。
差异化msi-h实体瘤适应症
“不限癌种”免疫治疗新选择
据统计，中国每年新发msi-h肿瘤患者逾30万，其中部分患者缺乏有效治疗，目前我国鲜有针对msi-h晚期实体瘤获批的pd-1抑制剂，临床治疗需求远未被满足，h药的获批为众多实体瘤患者带去新的治疗选择。astrum-010为一项针对msi-h实体瘤的单臂、多中心、关键性ii期临床研究，该试验的主要终点为独立影像评估委员会（irrc）依据recist v1.1标准评估的客观缓解率（orr）。该项临床试验结果曾分别于2021年asco年会、2021年csco年会上发布，此次asco年会上将公布该研究的更新数据。研究结果表明，h药单药治疗既往标准治疗失败的、不可切除或转移性msi-h实体瘤获益显著，达到预设的主要终点标准，且具有良好的安全性和耐受性。
未来，公司也将继续以患者需求为核心，凭借高效及创新的自主核心能力持续推进更多汉霖“质”造，为中国乃至全球患者提供最高品质的药物和服务，打造生物制药领域民族品牌。
关于h药 汉斯状®
h药 汉斯状®为重组人源化抗pd-1单抗注射液（通用名：斯鲁利单抗注射液），是复宏汉霖首个自主研发的创新型单抗，目前1项适应症获批上市，2项适应症上市申请获受理，9项临床试验同步在全球开展。
2022年3月，h药正式获批用于治疗微卫星高度不稳定（msi-h）实体瘤。围绕h药，复宏汉霖积极推进其与公司其他产品的协同以及与创新疗法的联合，相继获得中国、美国、欧盟等国家及地区的临床试验许可，在全球同步开展9项肿瘤免疫联合疗法临床试验，广泛覆盖肺癌、食管癌、头颈鳞癌和胃癌等适应症，全面覆盖肺癌一线治疗。截至目前，h药已于中国、土耳其、波兰、格鲁吉亚等国家和地区累计入组超2800人，其中2项国际多中心临床试验入组高加索人种的比例超过30%，是拥有国际临床数据较多的抗pd-1单抗之一。h药联合化疗治疗局部晚期或转移性鳞状非小细胞肺癌（sqnsclc）和一线治疗广泛期小细胞肺癌（es-sclc）的nda已获得nmpa受理并入选《2022 csco小细胞肺癌诊疗指南》作为es-sclc治疗推荐。此外，其治疗小细胞肺癌（sclc）也已获得美国fda孤儿药资格认定。公司亦计划于2022年在欧盟递交es-sclc的上市注册申请，有望成为全球首个一线治疗sclc的抗pd-1单抗。在一线治疗食管鳞癌领域，h药联合化疗iii期研究也已达到双主要研究终点。
关于复宏汉霖
复宏汉霖（2696.hk）是一家国际化的创新生物制药公司，致力于为全球患者提供可负担的高品质生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，已在中国上市5款产品，在欧洲上市1款产品，13项适应症获批，2个上市注册申请获得中国药监局受理。自2010年成立以来，复宏汉霖已建成一体化生物制药平台，高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心，按照国际药品生产质量管理规范（gmp）标准进行生产和质量管控，不断夯实一体化综合生产平台，其中，上海徐汇基地已获得中国和欧盟药品gmp认证，松江基地（一）也已获得中国gmp认证。
复宏汉霖前瞻性布局了一个多元化、高质量的产品管线，涵盖20多种创新单克隆抗体，并全面推进基于自有抗pd-1单抗h药汉斯状®的肿瘤免疫联合疗法。继国内首个生物类似药汉利康®（利妥昔单抗）、中国首个自主研发的中欧双批单抗药物汉曲优®（曲妥珠单抗，欧洲商品名：zercepac®）、汉达远®（阿达木单抗）和汉贝泰®（贝伐珠单抗）相继获批上市，创新产品汉斯状®（斯鲁利单抗）已获批用于治疗微卫星高度不稳定（msi-h）实体瘤，其鳞状非小细胞肺癌和广泛期小细胞肺癌两项适应症的上市注册申请也正在审评中。公司亦同步就12个产品、10个免疫联合治疗方案在全球范围内开展20多项临床试验，对外授权全面覆盖欧美主流生物药市场和众多新兴市场。
three clinical studies of novel anti-pd-1 mab serplulimab will be presented on 2022 asco annual meeting
shanghai, china, may 30th, 2022 – shanghai henlius biotech, inc. (2696.hk) announced that three clinical studies of hansizhuang (serplulimab), an anti-pd-1 mab independently developed by henlius, will be presented at 2022 american society of clinical oncology (asco) annual meeting. astrum-005, an international randomized phase 3 study of serplulimab as first-line treatment for extensive-stage small-cell lung cancer (es-sclc) was selected as an oral presentation by asco committee. the leading principal investigator is professor ying cheng from jilin cancer hospital. serplulimab is the first china-developed anti-pd-1 mab which will be presented orally at asco annual meeing in lung cancer. more detailed results of astrum-005 will be released on june 5th.
meanwhile, the updated results from the phase 2 study (astrum-010) of serplulimab in patients with microsatellite instability-high or mismatch repair-deficient (msi-h/dmmr) solid tumors was selected as a poster for the second time. astrum-010 was co-led by professor shukui qin from qinhuai medical area, eastern theater general hospital of pla china and professor jin li from shanghai east hospital, tongji university. based on the study results of astrum-010, serplulimab has been approved for the treatment of msi-h solid tumors by nmpa.
asco annual meeting is one of the most influential and important oncology congresses all over the world, aimed to display the latest advances in clinical oncology researches and therapeutic technologies for tumor treatment. the 2022 asco annual meeting will be held from june 3rd to june 7th cdt. details of three studies are as follows:
• astrum-005
title: serplulimab, a novel anti-pd-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: an international randomized phase 3 study (abstract no. 8505)
leading pi: ying cheng, jilin cancer hospital
form: oral presentation
session: oral abstract session/ lung cancer—non-small cell local-regional/small cell/other thoracic cancers
presentation time: june 5, 2022, 9:57 am - 10:09 am cdt
• astrum-010
title: updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-pd-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors (abstract no. 2592)
co-leading pi: shukui qin, qinhuai medical area, eastern theater general hospital of pla china; jin li, shanghai east hospital, tongji university
form: poster
time: june 3, 2022, cdt
• phase 1 study on solid tumors
title: a phase 1 study of serplulimab, a novel humanized monoclonal anti-pd-1 antibody, in patients with advanced solid tumors (abstract no. e14560)
form: abstract
being a breakthrough in sclc treatment, serplulimab shows the power of chinese innovation
small cell lung cancer (sclc) accounts for 15%–20% of all cases and is the most aggressive type of lung cancer. it is classified into two stages: limited stage (ls-sclc) and es-sclc, with both exhibiting high malignancy, strong invasiveness, early metastasis, fast disease progression, and a poor prognosis. the advent of immune checkpoint inhibitors has been proved to bring hope to patients with es-sclc.
astrum-005 is a randomized, double-blind, international, multi-center, phase 3 clinical study that aims to compare the efficacy and safety of hansizhuang with placebo when combined with chemotherapy (carboplatin-etoposide) in previously untreated patients with es-sclc. this study has set up a total of 128 sites in china, turkey, poland, georgia, etc. and enrolled 585 subjects from 114 sites, among whom 31.5% were caucasian. in december 2021, astrum-005 had met its primary study endpoint of the overall survival (os) in the interim analysis and demonstrated hansizhuang with a manageable safety profile. the global clinical data lays a solid foundation for future applications across the world.
previously, the nda of hansizhuang for the treatment of es-sclc has been accepted by nmpa. recently, hansizhuang was recommended by the 2022 csco guidelines for diagnosis and treatment of sclc for the treatment of es-sclc, stating the highly recognition for the efficacy and security of hansizhuang. in addition, the fda has granted orphan drug designation to hansizhuang for treatment of sclc, and henlius also plans to file maa on es-sclc in the eu in 2022.
the differentiated msi-h indication, "pan-cancer" treatment benefits a broader patient population
it is estimated that there are more than 300,000 new msi-h tumor cases in china every year, and some patients lack effective treatment. furthermore, there are few pd-1 inhibitors approved for msi-h advanced solid tumors in china currently. the clinical treatment demand is far from being met. astrum-010 is a single-arm, multi-center, pivotal phase 2 clinical study. the primary efficacy endpoint was objective response rate (orr) assessed by independent radiological review committee (irrc) per recist v1.1. this study results have been presented at the 2021 asco annual meeting and the 2021 csco annual meeting. at 2022 asco, we will present its updated data. the study has met its primary endpoint and brought significant benefits to unresectable or metastatic msi-h solid tumors patients who have failed to respond to previous standard treatments with good safety and tolerability.
in the future, henlius will keep focusing on patient needs and inspire more "made-by-henlius" products with efficient and innovative in-house capabilities, aiming to provide highest quality solutions and services for patients in china and across the world and to build a national brand in biopharmaceutical industry.
about hansizhuang
hansizhuang (recombinant humanized anti-pd-1 monoclonal antibody injection, generic name: serplulimab injection) is the first innovative monoclonal antibody developed by henlius. up to date, 1 indication is approved for marketing in china, 2 ndas have been accepted by the nmpa, and 9 clinical trials are ongoing across the world.
hansizhuang was approved by the nmpa for the treatment of msi-h solid tumors in march 2022 and actively promotes its synergy with in-house products of the company and innovative therapies. it has successively obtained clinical trial licenses in china, the united states, the european union and other countries and regions to initiate 9 clinical trials on immuno-oncology combination therapies worldwide in a wide variety of indications, such as lung cancer, esophageal carcinoma, head and neck squamous cell carcinoma and gastric cancer, etc., and covering the full range of first-line treatments of lung cancers. as of now, the company has enrolled more than 2,800 subjects in china, turkey, poland, georgia and other countries and regions, and the proportion of caucasian is over 30% in two mrcts, making hansizhuang an anti-pd-1 mab with one of the largest global clinical data pools. the ndas of the treatment for squamous non-small cell lung cancer (sqnsclc) and the first-line treatment of extensive small-cell lung cancer (es-sclc) have been accepted by the nmpa. furthermore, hansizhuang was recommended by the 2022 csco guidelines for diagnosis and treatment of small cell lung cancer (sclc) for the treatment of es-sclc and was also granted orphan drug designation by the fda for treatment of sclc. the maa of es-sclc is expected to be filed in the eu in 2022, which makes hansizhuang potentially the world’s first anti-pd-1 mab for the first-line treatment of sclc. in the field of esophageal squamous cell carcinoma, the phase 3 clinical trial of hansizhuang in combination with chemotherapy has met the co-primary endpoints.
about henlius
henlius (2696.hk) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. up to date, 5 products have been launched in china, 1 in europe, 13 indications approved worldwide, and 2 new drug application (nda) accepted for review in china. since its inception in 2010, henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including r&d, manufacturing and commercialization. it has established global innovation centers and shanghai-based manufacturing facilities in line with global good manufacturing practice (gmp), including xuhui plant certificated by china and the eu gmp and songjiang first plant certificated by china gmp.
henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mabs) and has continued to explore immuno-oncology combination therapies with proprietary hansizhuang (anti-pd-1 mab) as backbone. apart from the launched products hanlikang (rituximab), the first china-developed biosimilar, hanquyou (trastuzumab, trade name in europe: zercepac®), the first china-developed mab biosimilar approved both in china and europe, handayuan (adalimumab) and hanbeitai (bevacizumab), the innovative product hansizhuang has been approved by the nmpa for the treatment of msi-h solid tumors and its nda for the treatment of squamous non-small cell lung cancer and extensive small-cell lung cancer (es-sclc) are under review. what's more, henlius has conducted over 20 clinical studies for 12 products and 10 combination therapies.
